Maria Tsekoura1, Evdokia Billis1, John Gliatis2, Elias Tsepis1, Charalampos Matzaroglou1, Giorgios K Sakkas3, Charlotte Beaudart4, Olivier Bruyere4, Minos Tyllianakis2, Elias Panagiotopoulos5. 1. Department of Physiotherapy, School of Health and Caring Professions, Technological Educational Institute (ΤΕΙ) of Western Greece, Aigio, Greece. 2. Department of Orthopaedic Surgery, University Hospital of Patras, Rio, Greece. 3. Faculty of Sport and Health Sciences, University of St Mark & St John, Plymouth, UK. 4. Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium. 5. Department of Spinal Cord Injuries, University Hospital of Patras, Rio, Greece.
Abstract
Purpose: To translate and validate into the Greek language and setting the Sarcopenia Quality of Life (SarQoL®) questionnaire. Methods: A convenience sample of 176 Greek elderly people (136 females, 40 males; aged 71.19 ± 7.95 years) was recruited, 50 of which (36 females, 14 males) were diagnosed sarcopenic. Questionnaire was back-translated and culturally adapted into Greek according to international guidelines. To validate the Greek SarQoL®, we assessed its validity (discriminative power, construct validity), reliability (internal consistency, test-retest reliability) and floor/ceiling effects. Participants were divided into sarcopenic and non-sarcopenic. Sarcopenic subjects apart from the Greek SarQoL (SarQoLGR) filled out the Greek versions of two generic questionnaires; Short Form-36 and EuroQoL 5-dimension. Results: The Greek SarQoL questionnaire was translated without major difficulties. SarQoLGR mean scores were 52.12 ± 11.04 (range: 24.74-71.81) for sarcopenic subjects and 68.23 ± 14.1 (range: 24.83-94.81) for non-sarcopenic ones. Results indicated good discriminative power across sarcopenic and non-sarcopenic subjects (p = 0.01), high internal consistency (Cronbach's alpha of 0.96) and excellent test-retest reliability (ICC = 0.96, 95% CI = 0.95-0.97). Neither a floor nor a ceiling effect was observed.Conclusions: The Greek SarQoL was found to be a reliable and valid measure of quality of life for sarcopenic patients. It is therefore, available for use in future clinical research and practice.Implications for rehabilitationThe Greek version of the SarQoL® questionnaire is a valid and reliable outcome measure for assessing patients with sarcopenia.The Greek SarQoL is recommended to be use in clinical settings and research.The Greek SarQoL® questionnaire is available online www.sarqol.org.
Purpose: To translate and validate into the Greek language and setting the Sarcopenia Quality of Life (SarQoL®) questionnaire. Methods: A convenience sample of 176 Greek elderly people (136 females, 40 males; aged 71.19 ± 7.95 years) was recruited, 50 of which (36 females, 14 males) were diagnosed sarcopenic. Questionnaire was back-translated and culturally adapted into Greek according to international guidelines. To validate the Greek SarQoL®, we assessed its validity (discriminative power, construct validity), reliability (internal consistency, test-retest reliability) and floor/ceiling effects. Participants were divided into sarcopenic and non-sarcopenic. Sarcopenic subjects apart from the Greek SarQoL (SarQoLGR) filled out the Greek versions of two generic questionnaires; Short Form-36 and EuroQoL 5-dimension. Results: The Greek SarQoL questionnaire was translated without major difficulties. SarQoLGR mean scores were 52.12 ± 11.04 (range: 24.74-71.81) for sarcopenic subjects and 68.23 ± 14.1 (range: 24.83-94.81) for non-sarcopenic ones. Results indicated good discriminative power across sarcopenic and non-sarcopenic subjects (p = 0.01), high internal consistency (Cronbach's alpha of 0.96) and excellent test-retest reliability (ICC = 0.96, 95% CI = 0.95-0.97). Neither a floor nor a ceiling effect was observed.Conclusions: The Greek SarQoL was found to be a reliable and valid measure of quality of life for sarcopenic patients. It is therefore, available for use in future clinical research and practice.Implications for rehabilitationThe Greek version of the SarQoL® questionnaire is a valid and reliable outcome measure for assessing patients with sarcopenia.The Greek SarQoL is recommended to be use in clinical settings and research.The Greek SarQoL® questionnaire is available online www.sarqol.org.
Authors: Marta Dzhus; Maria Dzhus; Marta Masnyi; Myroslava Kulyk; Halyna Mostbauer; Oleksiy Ivashkivsky; Yaryna Boyko; Kateryna Cherchenko; Anton Geerinck; Jean-Yves Reginster; Olivier Bruyere; Charlotte Beaudart Journal: Ann Geriatr Med Res Date: 2020-06-15
Authors: María Visitación Martínez-Fernández; Irene Sandoval-Hernández; Alejandro Galán-Mercant; Manuel Gonzalez-Sanchez; Jesús Martínez-Cal; Guadalupe Molina-Torres Journal: Int J Environ Res Public Health Date: 2022-04-10 Impact factor: 4.614
Authors: A Geerinck; C Beaudart; J-Y Reginster; M Locquet; C Monseur; S Gillain; O Bruyère Journal: Qual Life Res Date: 2021-03-30 Impact factor: 4.147
Authors: Anton Geerinck; Vidmantas Alekna; Charlotte Beaudart; Ivan Bautmans; Cyrus Cooper; Fabiana De Souza Orlandi; Jerzy Konstantynowicz; Beatriz Montero-Errasquín; Eva Topinková; Maria Tsekoura; Jean-Yves Reginster; Olivier Bruyère Journal: PLoS One Date: 2019-04-29 Impact factor: 3.240